Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aclarion, Inc. stock logo
ACONW
Aclarion
$0.03
-25.0%
$0.04
$0.01
$0.42
N/AN/A26,240 shs19,189 shs
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
$0.01
$0.01
$0.00
$0.02
N/AN/A43,690 shs803 shs
SNDL Inc. stock logo
SNDL
SNDL
$2.30
-4.2%
$1.91
$1.25
$2.67
$381.85M3.286.47 million shs3.88 million shs
SXTPW
60 Degrees Pharmaceuticals
$0.11
$0.09
$0.03
$1.68
N/AN/A6,239 shs7 shs
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aclarion, Inc. stock logo
ACONW
Aclarion
-22.83%-30.23%+13.21%-39.64%-41.41%
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
-10.00%-11.96%-4.71%+39.66%-37.69%
SNDL Inc. stock logo
SNDL
SNDL
-4.37%-2.13%+11.11%+66.67%+27.07%
SXTPW
60 Degrees Pharmaceuticals
0.00%+5.00%-4.55%+320.00%+10,499,900.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aclarion, Inc. stock logo
ACONW
Aclarion
N/AN/AN/AN/AN/AN/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
SNDL Inc. stock logo
SNDL
SNDL
3.6008 of 5 stars
3.55.00.00.02.60.01.3
SXTPW
60 Degrees Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aclarion, Inc. stock logo
ACONW
Aclarion
N/AN/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/A
SNDL Inc. stock logo
SNDL
SNDL
3.00
Buy$4.0073.91% Upside
SXTPW
60 Degrees Pharmaceuticals
N/AN/AN/AN/A

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aclarion, Inc. stock logo
ACONW
Aclarion
$75.40KN/AN/AN/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/AN/A
SNDL Inc. stock logo
SNDL
SNDL
$909.01M0.42N/AN/A$6.15 per share0.37
SXTPW
60 Degrees Pharmaceuticals
$253.57KN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aclarion, Inc. stock logo
ACONW
Aclarion
N/AN/A0.00N/AN/AN/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/A0.00N/AN/AN/AN/AN/A
SNDL Inc. stock logo
SNDL
SNDL
-$127.91M-$0.40N/A57.50N/A-14.99%-9.87%-8.31%8/12/2024 (Estimated)
SXTPW
60 Degrees Pharmaceuticals
N/AN/A0.00N/AN/AN/AN/AN/A

Latest SNDL, ATNFW, SXTPW, and ACONW Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2024Q1 2024
SNDL Inc. stock logo
SNDL
SNDL
-$0.04-$0.01+$0.03-$0.01$154.88 million$146.69 million    
3/20/2024Q4 2023
SNDL Inc. stock logo
SNDL
SNDL
-$0.12-$0.22-$0.10-$0.20$178.85 million$182.51 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aclarion, Inc. stock logo
ACONW
Aclarion
N/AN/AN/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/A
SNDL Inc. stock logo
SNDL
SNDL
N/AN/AN/AN/AN/A
SXTPW
60 Degrees Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aclarion, Inc. stock logo
ACONW
Aclarion
N/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/A
SNDL Inc. stock logo
SNDL
SNDL
0.11
3.94
2.69
SXTPW
60 Degrees Pharmaceuticals
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Aclarion, Inc. stock logo
ACONW
Aclarion
N/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/A
SNDL Inc. stock logo
SNDL
SNDL
N/A
SXTPW
60 Degrees Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
Aclarion, Inc. stock logo
ACONW
Aclarion
N/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/A
SNDL Inc. stock logo
SNDL
SNDL
N/A
SXTPW
60 Degrees Pharmaceuticals
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Aclarion, Inc. stock logo
ACONW
Aclarion
4N/AN/ANot Optionable
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
4N/AN/ANot Optionable
SNDL Inc. stock logo
SNDL
SNDL
2,516166.02 millionN/AOptionable
SXTPW
60 Degrees Pharmaceuticals
2N/AN/ANot Optionable

SNDL, ATNFW, SXTPW, and ACONW Headlines

No headlines for this company have been tracked by MarketBeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aclarion logo

Aclarion

NASDAQ:ACONW
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
180 Life Sciences logo

180 Life Sciences

NASDAQ:ATNFW
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.
SNDL logo

SNDL

NASDAQ:SNDL
SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.

60 Degrees Pharmaceuticals

NASDAQ:SXTPW
60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.